

PLEASE STAMP TO ACKNOWLEDGE RECEIPT OF THE FOLLOWING:

In Re Application of: BLUSZTAJN et al.

Application No.: 09/656,935

Group Art Unit: 1632

Filed: September 7, 2000

Examiner: Anne Marie Falk

For: BMP-9 COMPOSITIONS AND METHODS FOR INDUCING DIFFERENTIATION OF
CHOLINERGIC NEURONS

1. Information Disclosure Statement Under 37 C.F.R. §1.97(c) (2 pages)
2. PTO-Form 1449 (4 pages)
3. References as cited
4. Check in the amount of \$180.00

RECEIVED

JAN 13 2003

TECH CENTER 1600/2900

Dated: January 10, 2003

Docket No.: 08702.0069-00000

(Due Date: N/D/D)

EEM/kmb - Mail Drop CAMB



Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final action, Quayle action, or a Notice of Allowance. Under the provisions of 37 C.F.R. § 1.97(c), this Information Disclosure Statement is accompanied by a fee of \$180.00 as specified by Section 1.17(p).

Each document listed in this Information Disclosure Statement was first cited in a communication from the Patent Cooperation Treaty in a counterpart foreign application.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

103
PATENT

Customer No. 22,852

Attorney Docket No. 08702.0069-00000



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Jan Krzysztof Blusztajn et al.

Application No.: 09/656,935

Filed: September 7, 2000

For: BMP-9 COMPOSITIONS AND
METHODS FOR INDUCING
DIFFERENTIATION OF
CHOLINERGIC NEURONS

Commissioner for Patents
Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), applicant brings to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final action, Quayle action, or a Notice of Allowance. Under the provisions of 37 C.F.R. § 1.97(c), this Information Disclosure Statement is accompanied by a fee of \$180.00 as specified by Section 1.17(p).

Each document listed in this Information Disclosure Statement was first cited in a communication from the Patent Cooperation Treaty in a counterpart foreign application.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

RECEIVED
JAN 3 0 2003
TECH CENTER 1600/2900

RECEIVED

JAN 13 2003

TECH CENTER 1600/2900

PATENT
Customer No. 22,852
Attorney Docket No. 08702.0069-00000

Copies of the listed documents, including any copending patent applications, are attached.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claims in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: January 10, 2003

By: _____
Ellen J. Kapinos
Reg. No. 32,245

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com




OMB No. 0651-0011

RECEIVED

INFORMATION DISCLOSURE CITATION

Atty. Docket No. 702.0069-00000	Appln. No. 09/656,935	JAN 13 2003
Applicant	Jan Krzysztof Blusztajn et al.	
Filing Date	September 7, 2000	Group: 1632

U.S. PATENT DOCUMENTS						
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	5,108,753	4/28/92	Kuberasampath	424	422	
	5,106,626	4/21/92	Parsons et al.	424	423	
	5,011,691	4/30/91	Oppermann	424	423	
	4,968,590	11/6/90	Kuberasampath and Rueger	530	326	
	4,886,747	12/12/89	Derynck	435	69.4	
	4,843,063	6/27/89	Seyedin	514	2	JAN 30 2003 TECH CENTER 1600 RECEIVED
	4,810,691	3/7/89	Seyedin	514	2	13 O
	4,804,744	2/14/89	Sen	530	350	
	4,795,804	1/19/89	Urist	530	350	
	4,798,885	1/17/89	Mason	530	350	
	4,789,732	12/6/88	Urist	530	350	
	4,774,322	9/27/88	Seyedin	530	353	
	4,774,228	9/27/88	Seyedin	514	21	
	4,761,471	8/2/88	Urist	530	350	
	4,737,578	4/12/88	Evans	530	350	
	4,681,763	7/21/87	Nathanson	424	95	
	4,627,982	12/9/86	Seyedin and Thomas	424	95	
	4,619,989	10/19/86	Urist	530	417	
	4,608,199	8/26/86	Caplan and Syftestad	530	414	
	4,563,350	1/7/86	Nathan	424	95	
	4,455,256	6/19/84	Urist	530	350	
	4,434,094	2/28/84	Seyedin and Thomas	530	416	
	4,294,753	10/31/81	Urist	530	395	
	5,661,007	8/26/97	Wozney	435	69.4	



OMB No. 0651-0011

INFORMATION DISCLOSURE CITATION

Atty. Docket No. 0069-00000	Appln. No. 09/656,935	RECEIVED
Applicant Jan Krzysztof Blusztajn et al.	JAN 13 2003	
Filing Date September 7, 2000	Group: 1632	TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	WO 99/01159	1/14/99	WIPO			
	WO 93/05751	4/1/93	WIPO	A61K		
	WO 93/04692	3/18/93	WIPO	A61K	37/02	
	WO 92/07073	4/30/92	WIPO	C12N	15/00	
	WO 92/07004	4/30/92	WIPO	C07K	15/06	
	WO 91/18047	11/28/91	WIPO			
	WO 91/05802	5/2/91	WIPO	C07K	15/00	
	WO 91/02744	3/7/91	WIPO	C07K	15/06	
	4 094 72 A1	11/7/90	European Patent Appln.	C12N	15/12	
	2 017466	5/24/90	Canada	C12N	15/16	
	4 165 78A2	5/9/90	European Patent Appln.	C12N	15/00	
	WO 90/03733	4/19/90	WIPO	A01N	63/02	
	WO 89/09787	10/29/89	WIPO	C07K	13/00	
	WO 89/09788	10/19/89	WIPO	C07K	13/00	
	33 6760	6/4/89	European Patent Appln.	C07K	7/00	
	WO 91/18098	11/28/91	WIPO			
	WO 90/11366	10/4/90	WIPO			

RECEIVED
JAN 30 2003
TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	International Search Report, mailed 13 March 2001 for PCT/US00/24555.
	Baird et al., "Inhibition of endothelial cell proliferation by type-beta transforming growth factor: interactions with acidic and basic fibroblast growth factors," <i>Biochem. Biophys. Res. Commun.</i> Vol. 138:476-482 (1986).
	Beck et al., "Accelerated healing of ulcer wounds in the rabbit ear by recombinant human transforming growth-beta 1," <i>Growth Factors</i> , Vol. 2:273-282 (1990).
	Bowie et al., "Deciphering the message in protein sequences: tolerance to amino acid substitutions," <i>Science</i> 247 (4948):1306-1310 (1990).



OMB No. 0651-0011

INFORMATION DISCLOSURE CITATION

Atty. Docket No. 0969-00000	Appln. No. 09/656,935	RECEIVED JAN 13 2003 TECH CENTER 1600/2900
Applicant Jan Krzysztof Blusztajn et al.		
Filing Date September 7, 2000	Group: 1632	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Burt et al., "Evolutionary grouping of the transforming growth factor- β superfamily," <i>BBRC</i> 184(2):590-595 (1992).
Celeste et al., <i>J. of Bone Mineral Res.</i> v. 9 suppl. 5136 (1994).
Celeste et al., "Identification of transforming growth factor β family members," <i>Proc. Natl. Acad. Sci.</i> 87:9843-9847 (1990).
Hammonds et al., <i>Molecular Endocrinology</i> 5:149-155 (1991).
Hebda et al., "Stimulatory effects of transforming growth factor -beta and epidermal growth factor on epidermal cell outgrowth from porcine skin explant cultures," <i>J. Invest. Dermatol.</i> , Vol. 91:440-445 (1988).
Marieb I N. In, <i>Human Anatomy and Physiology</i> , Second Edition. 1992. The Benjamin/Cummings Publishing Co., Inc. pages 373-375.
McDonald et al., "A structural superfamily of growth factors containing a cystine knot motif," <i>Cell</i> , Vol. 73:421-424 (1993).
Leslie M. "Hyaluronic acid treatment for osteoarthritis of the knee," <i>Nurse Practitioner</i> 24(7)38:41-48 (1999).
Lodish et al. <i>Molecular Cell Biology</i> , 3 rd edition, W.H. Freeman & Co. page 196 (1995).
Lopez-Coviella, et al., "Bone morphogenetic proteins (BMPs) as cholinergic differentiating factors for basal forebrain neurons," <i>Society for Neuroscience Abstracts</i> , 25 (Pt. 1): 517 (1999)
Lopez-Coviella, et al., "Induction and maintenance of the neuronal cholinergic phenotype in the central nervous system by BMP-9," <i>Science</i> , 289 (5477): 313-316 (2000)
Lyons et al., <i>Proc. Natl. Sci. USA</i> , Vol. 86:4554-4558 (1989).
Luyten et al., <i>The Journal of Biological Chemistry</i> 264(23): 13377-13380 (1989).
Nathan et al., "Cytokines in context," <i>Journal of Cell Biology</i> 113 (5):981-986 (1991).
Ozkaynak et al., <i>The EMBO Journal</i> v. 9 No. 7:2085-2093 (1990).
Peyron G. "Is osteoarthritis a preventable disease?" <i>Journal of Rheumatology</i> . Supplement 22-3 (1991).
Roberts et al., "Transforming growth factor type-beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 83:4167-4171 (1986).
Sambrook et al. <i>Molecular Cloning: A Laboratory Manual</i> Second Edition Vols. 1, 2 and 3. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York, U.S.A. November 1989.
Sampath et al., <i>Proc. Natl. Acad. Sci.</i> 84:7109-7113 (1987).
Shipley et al., "Reversible inhibition of normal human prokeratinocyte proliferation by type beta transforming growth factor-growth inhibitor in serum-free medium," <i>Cancer Res.</i> , Vol. 46:2068-2071 (1986).

TECH CENTER 1600/2900
JAN 30 2003

RECEIVED



INFORMATION DISCLOSURE CITATION

Atty. Docket No. RADEK 02.0069-00000	Appln. No. 09/656,935
Applicant	Jan Krzysztof Blusztajn <i>et al.</i>
Filing Date	September 7, 2000
	Group: 1632

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Sporn et al., "Peptide growth factors are multifunctional," <i>Nature</i> , Vol 332:217-219 (1988).
	Urist et al., <i>Science</i> , 220: 680-686 (1983).
	Wang et al., "Recombinant human bone morphogenetic protein induces bone formation," <i>Proc. Natl. Acad. Sci.</i> 87:2220-2224 (1990).
	Wozney et al., In <i>Handbook of Exp. Pharm.</i> Vol. 107, 1993 Springer-Verlag, Berlin, pages 725-748.
	Wozney et al., "Growth factors influencing bone development," <i>J. Cell Sci. Suppl.</i> 13:149-156 (1990).
	Wozney et al., "Novel regulators of bone formation: molecular clones and activities," <i>Science</i> 242:1528-1534 (1988).

Examiner	Date Considered
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449

Patent and Trademark Office - U.S. Department of Commerce

RECEIVED
JAN 3 0 2003
TECH CENTER 1600/2900

RECEIVED
JAN 13 2003
TECH CENTER 1600/2900